CAJ | 학술논문

目的评价雷贝拉唑钠肠溶胶囊与阿莫西林克拉维酸钾分散片联合呋喃唑酮或左氧氟沙星对根除幽门螺杆菌的临床疗效和依从性.方法 249例幽门螺杆菌阳性患者随机分成3组,A组81例给予雷贝拉唑钠肠溶胶囊20 mg、阿莫西林克拉维酸钾分散片3片、呋喃唑酮片100 mg,每日2次,早、晚饭前口服.B组83例给予雷贝拉唑钠肠溶胶囊20 mg、阿莫西林克拉维酸钾分散片3片、左氧氟沙星片200 mg,每日2次,早、晚饭前口服.C组85例给予雷贝拉唑钠肠溶胶囊20 mg、克拉霉素胶囊500 mg、阿莫西林分散片1 000mg,每日2次,早、晚饭前口服.疗程均为10 d.结果 A组幽门螺杆菌根除率为93.83％(76/81)、B组为89.16％(74/83)、C组为81.18％(69/85),A组根除率明显优于C组(P＜0.05),A组与B组比较及B组与C组比较差异均无统计学意义(P均＞0.05).主要消化道症状平均总积分3组分别从(12.52±2.24)、(12.30±2.42)、(12.61±2.01)分降至疗程结束4周后的(3.16±2.23)、(3.58±2.39)、(4.78±2.28)分,A组和B组疗效均显著优于C组(P＜0.05).不良反应发生率3组分别为11.11％、30.12％、62.35％,A组和B组明显低于C组(P均＜0.05),A组亦低于B组(P＜0.05).依从性分布比较,A组最好、B组次之、C组最差,3组间比较差异均有统计学意义(P均＜0.05).结论雷贝拉唑钠肠溶胶囊与阿莫西林克拉维酸钾分散片联合呋喃唑酮三联疗法治疗幽门螺杆菌感染效果最佳.
목적 평개뢰패랍서납장용효낭여아막서림극랍유산갑분산편연합부남서동혹좌양불사성대근제유문라간균적림상료효화의종성.방법 249례유문라간균양성환자수궤분성3조,A조81례급여뢰패랍서납장용효낭20 mg、아막서림극랍유산갑분산편3편、부남서동편100 mg,매일2차,조、만반전구복.B조83례급여뢰패랍서납장용효낭20 mg、아막서림극랍유산갑분산편3편、좌양불사성편200 mg,매일2차,조、만반전구복.C조85례급여뢰패랍서납장용효낭20 mg、극랍매소효낭500 mg、아막서림분산편1 000mg,매일2차,조、만반전구복.료정균위10 d.결과 A조유문라간균근제솔위93.83％(76/81)、B조위89.16％(74/83)、C조위81.18％(69/85),A조근제솔명현우우C조(P＜0.05),A조여B조비교급B조여C조비교차이균무통계학의의(P균＞0.05).주요소화도증상평균총적분3조분별종(12.52±2.24)、(12.30±2.42)、(12.61±2.01)분강지료정결속4주후적(3.16±2.23)、(3.58±2.39)、(4.78±2.28)분,A조화B조료효균현저우우C조(P＜0.05).불량반응발생솔3조분별위11.11％、30.12％、62.35％,A조화B조명현저우C조(P균＜0.05),A조역저우B조(P＜0.05).의종성분포비교,A조최호、B조차지、C조최차,3조간비교차이균유통계학의의(P균＜0.05).결론 뢰패랍서납장용효낭여아막서림극랍유산갑분산편연합부남서동삼련요법치료유문라간균감염효과최가.
Objective To evaluate the effect of treatment and compliance of rebeparzole sodium enteric coated capsules, amoxicillin and clavulanate potassium tablets and furazolidon or levofloxacine treatment of helicobacter pylori infection.Methods Two hundred and forty-nine cases of positive helicobacter pylori infection were randomly divided into three groups.Eighty-one cases of Group A were treated with rebeparzole sodium enteric-coted capsules (20 mg one time), amoxicillin and clavulanate potassium tablets (3 tablets one time) and furazolidon(100 mg one time) ,twice a day before breakfast and supper.Eighty-three cases of Group B were treated with rebeparzole sodium enteric-coted capsules (20 mg one time), amoxicillin and clavulanate potassium tablets (3 tablets one time) and levofloxacine (200 mg one time), twice a day before breakfast and supper.Eighty-five cases of Group C were treated with rebeparzole sodium enteric-coted capsules (20 mg one time) ,clarithromycin capsules(500 mg one time) and amoxicillin dispersible tablets(1 000 mg one time) ,twice a day before breakfast and supper.Period of treatment was 10 days.Results The helicobacter pylori eradication rate of Group A,B and C were 93.83％(76/81) ,89.16％(74/83) and 81.18％(69/85).The eradication rate of Group A was higher than that of Group C (P＜0.05).The comparison between Group A and Group B and between Group B and Group C had no statistically significant difference(P＞0.05).Total integral in average of main digestive symptoms respectively decreased from 12.52±2.24, 12.30±2.42,12.61±2.01 to 3.16±2.23, 3.58±2.39,4.78±2.28 after four-week treatment.The effect of treatment of Group A and Group B was much better than that of Group C(P＜0.05).The incidence of adverse reaction were 11.11％, 30.12％ and 62.35％respectively.Group A and Group B were much lower than Group C (P ＜ 0.05), and Group A was lower than Group B(P＜0.05).In the comparison of the spread of compliance, Group A was the best, the next was Group B,and the last was Group C.The comparison result of those 3 groups was statistically significant (P ＜0.05).Conclusion Ray rabeprazole sodium enteric coated capsules and amoxicillin and clavulanate potassium dispersion tablets combined with furazolidone furazolidone triple therapy in the treatment of Helicobacter pylori Helicobacter pylori infection effect is the best.